The BCR-ABL inhibitor ponatinib inhibits platelet immunoreceptor tyrosine-based activation motif (ITAM) signaling, platelet activation and aggregate formation under shear

BACKGROUND: Treatment of chronic myelogenous leukemia (CML) with the BCR-ABL tyrosine kinase inhibitor (TKI) imatinib significantly improves patient outcomes. As some patients are unresponsive to imatinib, next generation BCR-ABL inhibitors such as nilotinib have been developed to treat patients wit...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Thromb Res
Main Authors: Loren, Cassandra P., Aslan, Joseph E., Rigg, Rachel A., Nowak, Marie S., Healy, Laura D., Gruber, András, Druker, Brian J., McCarty, Owen J. T.
Formato: Artigo
Idioma:Inglês
Publicado em: 2014
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4272760/
https://ncbi.nlm.nih.gov/pubmed/25527332
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.thromres.2014.11.009
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados